-
Je něco špatně v tomto záznamu ?
Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network
F. Espinosa-Ortega, K. Lodin, M. Dastmalchi, J. Vencovsky, LP. Diederichsen, SK. Shinjo, MG. Danieli, A. Selva-O'Callaghan, M. de Visser, Z. Griger, A. Ceribelli, D. Gómez-Martin, H. Andersson, M. Vázquez-Del Mercado, H. Chinoy, JB. Lilleker, P....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- autoprotilátky * krev imunologie MeSH
- dermatomyozitida imunologie krev MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- myozitida * imunologie krev MeSH
- progrese nemoci MeSH
- registrace * MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: To study the trajectories of changes in damage over time and explore associations with autoantibody defined subgroups using a large international cohort of patients with idiopathic inflammatory myopathies (IIM). METHODS: Data from the MYONET registry, including patients who were tested for autoantibodies and had at least one assessment of damage using the Myositis Damage Index (MDI), were analyzed. Patients were sub-grouped according to their autoantibody profiles (myositis-specific, myositis-associated, or seronegative). The index date was defined as the time point for the first registered MDI assessment. The longitudinal trajectories of damage with autoantibody status as the main predictor were analyzed using linear mixed models. RESULTS: A total of 757 adult patients were included in this study. Each year of disease duration since diagnosis had an estimated MDI score increase of 0.16 units for the seronegative group (reference). Compared with the seronegative group as reference, patients with dermatomyositis-specific autoantibodies developed less damage per year of follow-up since diagnosis (average 0.08 less score, P = 0.04), whereas patients with anti-PM/Scl autoantibodies developed more damage per year of follow-up since diagnosis (average 0.28 higher score, P = 0.03) independent of sex and age at diagnosis. The seronegative subgroup and the immune-mediated necrotizing myopathy autoantibody subgroup had the strongest correlation between severity of muscle damage and HAQ-DI scores at five years of follow-up, rho=0.84, P < 0.001 and rho=0.72, P < 0.001, respectively. CONCLUSION: Our study is the first to describe patterns and trajectories of change in damage over time in relation to autoantibody defined subgroups in a large international multicenter cohort of patients with IIM. Patients with anti-PM/Scl scored a greater extent of damage, whereas patients with dermatomyositis-specific antibodies had less damage than seronegative patients. Severity in muscle damage had moderate to strong correlation with functional disability among the IMNM and seronegative subgroups with lower correlations for the other subgroups. These findings suggest that autoantibodies may be useful predictors of long-term damage.
Department of Biomedical Sciences Humanitas University Milan Italy
Department of Gastro Dermatology and Rheumatology Karolinska University Hospital Stockholm Sweden
Department of Rheumatology Odense University Hospital Odense Denmark
Department of Rheumatology Oslo University Hospital Oslo Norway
Division of Rheumatology Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Division of Rheumatology Faculdade de Medicina FMUSP Universidade de Sao Paulo Sao Paulo SP Brazil
Faculty of Medicine Division of Clinical Immunology University of Debrecen Hungary
Systemic Autoimmune Diseases Unit Vall d'Hebron Hospital Universitat Autonoma de Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018753
- 003
- CZ-PrNML
- 005
- 20241024111343.0
- 007
- ta
- 008
- 241015e20240808xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.semarthrit.2024.152529 $2 doi
- 035 __
- $a (PubMed)39178739
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Espinosa-Ortega, Fabricio $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden. Electronic address: fabricio.espinosa@ki.se
- 245 10
- $a Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network / $c F. Espinosa-Ortega, K. Lodin, M. Dastmalchi, J. Vencovsky, LP. Diederichsen, SK. Shinjo, MG. Danieli, A. Selva-O'Callaghan, M. de Visser, Z. Griger, A. Ceribelli, D. Gómez-Martin, H. Andersson, M. Vázquez-Del Mercado, H. Chinoy, JB. Lilleker, P. New, NS. Krogh, IE. Lundberg, H. Alexanderson, MYONET Registry Study Group
- 520 9_
- $a OBJECTIVE: To study the trajectories of changes in damage over time and explore associations with autoantibody defined subgroups using a large international cohort of patients with idiopathic inflammatory myopathies (IIM). METHODS: Data from the MYONET registry, including patients who were tested for autoantibodies and had at least one assessment of damage using the Myositis Damage Index (MDI), were analyzed. Patients were sub-grouped according to their autoantibody profiles (myositis-specific, myositis-associated, or seronegative). The index date was defined as the time point for the first registered MDI assessment. The longitudinal trajectories of damage with autoantibody status as the main predictor were analyzed using linear mixed models. RESULTS: A total of 757 adult patients were included in this study. Each year of disease duration since diagnosis had an estimated MDI score increase of 0.16 units for the seronegative group (reference). Compared with the seronegative group as reference, patients with dermatomyositis-specific autoantibodies developed less damage per year of follow-up since diagnosis (average 0.08 less score, P = 0.04), whereas patients with anti-PM/Scl autoantibodies developed more damage per year of follow-up since diagnosis (average 0.28 higher score, P = 0.03) independent of sex and age at diagnosis. The seronegative subgroup and the immune-mediated necrotizing myopathy autoantibody subgroup had the strongest correlation between severity of muscle damage and HAQ-DI scores at five years of follow-up, rho=0.84, P < 0.001 and rho=0.72, P < 0.001, respectively. CONCLUSION: Our study is the first to describe patterns and trajectories of change in damage over time in relation to autoantibody defined subgroups in a large international multicenter cohort of patients with IIM. Patients with anti-PM/Scl scored a greater extent of damage, whereas patients with dermatomyositis-specific antibodies had less damage than seronegative patients. Severity in muscle damage had moderate to strong correlation with functional disability among the IMNM and seronegative subgroups with lower correlations for the other subgroups. These findings suggest that autoantibodies may be useful predictors of long-term damage.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a autoprotilátky $x krev $x imunologie $7 D001323
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a myozitida $x imunologie $x krev $7 D009220
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a registrace $7 D012042
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a dermatomyozitida $x imunologie $x krev $7 D003882
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Lodin, Karin $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Dastmalchi, Maryam $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
- 700 1_
- $a Diederichsen, Louise P $u Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Rheumatology, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Shinjo, Samuel Katsuyuki $u Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
- 700 1_
- $a Danieli, Maria Giovanna $u Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Torrette di Ancona, Italy
- 700 1_
- $a Selva-O'Callaghan, Albert $u Systemic Autoimmune Diseases Unit, Vall d'Hebron Hospital, Universitat Autonoma de Barcelona, Spain
- 700 1_
- $a de Visser, Marianne $u Department of Neurology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands
- 700 1_
- $a Griger, Zoltan $u Faculty of Medicine, Division of Clinical Immunology, University of Debrecen, Hungary
- 700 1_
- $a Ceribelli, Angela $u Division of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy
- 700 1_
- $a Gómez-Martin, Diana $u Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Dr Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Andersson, Helena $u Department of Rheumatology, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Vázquez-Del Mercado, Mónica $u División de Medicina Interna, Servicio de Reumatología, Hospital Civil Dr Juan I Menchaca, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- 700 1_
- $a Chinoy, Hector $u Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK; Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK
- 700 1_
- $a Lilleker, James B $u Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK
- 700 1_
- $a New, Paul $u Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK; Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK
- 700 1_
- $a Krogh, Niels S $u Zitelab Aps, Copenhagen, Denmark
- 700 1_
- $a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Alexanderson, Helene $u Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Theme Women's Health and Health Professionals, Medical Unit Allied Health Professionals, Karolinska University Hospital, Stockholm, Sweden
- 710 2_
- $a MYONET Registry Study Group
- 773 0_
- $w MED00004315 $t Seminars in arthritis and rheumatism $x 1532-866X $g Roč. 68 (20240808), s. 152529
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39178739 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111336 $b ABA008
- 999 __
- $a ok $b bmc $g 2201552 $s 1230726
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 68 $c - $d 152529 $e 20240808 $i 1532-866X $m Seminars in arthritis and rheumatism $n Semin Arthritis Rheum $x MED00004315
- LZP __
- $a Pubmed-20241015
